<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77181">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01840345</url>
  </required_header>
  <id_info>
    <org_study_id>NAC in Chronic Pain</org_study_id>
    <nct_id>NCT01840345</nct_id>
  </id_info>
  <brief_title>The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain</brief_title>
  <official_title>The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test whether treatment with N-acetyl-L-cysteine (NAC) is safe and decreases
      pain in patients with chronic neuropathic pain. The investigators hypothesize that NAC will
      be a useful adjunct to opioid treatment in chronic neuropathic pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label study to evaluate the safety and efficacy of N-acetyl-L-cysteine in
      patients with Chronic neuropathic pain.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Opioid use</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured in morphine equivalents</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>VAS Pain Quality Assessment Scale Pain Disability Index Pain Catastrophizing Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>PHQ-9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>PSS</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>N-acetyl-L-cysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n-acetyl-l-cysteine 1200 mg BID x 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetyl-l-cysteine</intervention_name>
    <description>1200 mg BID x 4 weeks</description>
    <arm_group_label>N-acetyl-L-cysteine</arm_group_label>
    <other_name>NAC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-65 years old

          -  non-cancer neuropathic pain

          -  stable dose of opioids for pain

          -  using breakthrough pain meds

          -  still with persistent pain per VAS

        Exclusion Criteria:

          -  pregnant or nursing

          -  serious medical or psychiatric illness

          -  active stomach ulcer, history or seizures or asthma

          -  breakthrough pain meds other than opioids

          -  using illicit drugs
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael F Weaver, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael F Weaver, MD</last_name>
    <phone>804-827-1519</phone>
    <email>mfweaver@mcvh-vcu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pamela Dillon, PharmD</last_name>
    <phone>804-827-1519</phone>
    <email>pmdillon@vcu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pamela Dillon, PharmD</last_name>
      <phone>804-827-1519</phone>
      <email>pmdillon@vcu.edu</email>
    </contact>
    <investigator>
      <last_name>Michael F Weaver, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 19, 2013</lastchanged_date>
  <firstreceived_date>April 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uncontrolled</keyword>
  <keyword>neuropathic pain</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
    <mesh_term>Analgesics, Opioid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
